Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer

Cancer

Volumn 113, Issue 3, 2008, Pages 542-546

  Ramalingam, Suresh ^a   Perry, Michael C ^b   La Rocca, Renato V ^c   Rinaldi, David ^d   Gable, Preston S ^e   Tester, William J ^f   Belani, Chandra P ^g  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Kentuckiana Cancer Institute   (United States)

^d Louisiana Oncology Associates   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f ALBERT EINSTEIN MEDICAL CENTER   (United States)

^g PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Elderly; Nonsmall cell lung cancer; Paclitaxel; Weekly schedule

Indexed keywords

CARBOPLATIN; PACLITAXEL;

AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEURITIS; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49049113050     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23583     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol. 2004;31(suppl 1):68-74.
3. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570-5577.
4. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163-184.
5. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
6. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66-72.
7. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-372.
8. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70 years) [abstract]. Proc Am Soc Clin Oncol. 2003;22:639. Abstract 2569.
9. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005;104:2766-2774.
10. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23:190-196.
11. Ramalingam S, Barstis J, Perry MC, et al. Treatment of elderly non-small cell lung cancer (NSCLC) patients with 3 different schedules of weekly paclitaxel in combination with carboplatin: sub-analysis of a randomized trial. J Thorac Oncol. 2006;1:240-244.
12. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:468-473.
13. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
15. Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother. 2002;3:1693-1709.
16. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21:2933-2939.
17. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760-766.